<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00337389</url>
  </required_header>
  <id_info>
    <org_study_id>510-05</org_study_id>
    <nct_id>NCT00337389</nct_id>
  </id_info>
  <brief_title>Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.</brief_title>
  <official_title>A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      To compare the progression-free survival time (PFS) in patients treated with 5-FU modulated&#xD;
      with CoFactor (plus bevacizumab) to 5-FU modulated with leucovorin (plus bevacizumab) in&#xD;
      patients with Metastatic Colorectal Cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CoFactor, 5-FU, Avastin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Leucovorin, 5-FU, Avastin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5- Fluorouracil (5-FU)</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab (Avastin)</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CoFactor (ANX-510)</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Greater or equal to 18 years of age.&#xD;
&#xD;
          2. Surgically incurable, metastatic disease from proven colon or rectal adenocarcinoma.&#xD;
&#xD;
          3. Life expectancy of at least 3 months.&#xD;
&#xD;
          4. Histologically confirmed metastatic disease. Histological confirmation may be waived&#xD;
             if needle biopsy presents a significant risk to the subject and the clinical setting&#xD;
             is clinically consistent with metastasis of colorectal cancer, e.g. surgical findings&#xD;
             at laparotomy, or positive PET scan, synchronous histologically confirmed primary&#xD;
             tumor with typical metastatic pattern (stage D disease). Waiver can only be granted by&#xD;
             the Sponsor, and these cases will be kept to less than 10% of the total study&#xD;
             population.&#xD;
&#xD;
          5. Measurable disease. At least one unidimensionally measurable lesion with a diameter&#xD;
             ≥10 mm using spiral CT scans (use of spiral CT must be documented in medical records&#xD;
             and used consistently throughout the study) or ≥20 mm using conventional CT or MRI&#xD;
             scans.&#xD;
&#xD;
          6. No prior systemic chemotherapy or immunotherapy for metastatic or advanced local&#xD;
             disease. However patients may have had radiosensitizing doses of fluoropyrimidines&#xD;
             (only 5-FU or capecitabine, with or without leucovorin or levamisole is permitted) if&#xD;
             completed 6 months prior to treatment on this protocol. No prior irinotecan or&#xD;
             oxaliplatin in combination with radiotherapy is allowed.&#xD;
&#xD;
          7. Prior adjuvant therapy is allowed if completed more than 6 months prior to treatment&#xD;
             on this protocol. Regimens which included oxaliplatin and irinotecan are allowed.&#xD;
&#xD;
          8. ECOG Performance Status is 0-2 or Karnofsky performance level of 100-70.&#xD;
&#xD;
          9. Willing and able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior exposure to bevacizumab.&#xD;
&#xD;
          2. A known intolerance to fluoropyrimidine (5-FU, capecitabine, floxuridine, UFT) therapy&#xD;
             suggestive of dihydropyrimidine dehydrogenase (DPD) deficiency.&#xD;
&#xD;
          3. Use of the following drugs are not permitted on the protocol: sorivudine (or other&#xD;
             nucleoside analogue), or Brivudin™ (or other DPD inhibitor).&#xD;
&#xD;
          4. Pregnancy or lactation. Women with a positive (or no) serum or urine pregnancy test&#xD;
             within 15 days of Cycle 1 Week 1. Women must have been amenorrheic for at least 12&#xD;
             consecutive months to be considered to lack potential for child bearing.&#xD;
&#xD;
          5. If sexually active and of child-bearing potential, failure to agree to use adequate&#xD;
             contraception during this study and for 60 days after discontinuation of study&#xD;
             medication.&#xD;
&#xD;
          6. A concurrent infection, including diagnoses of FUO and evidence of possible central&#xD;
             line sepsis (subjects must be afebrile at the start of therapy).&#xD;
&#xD;
          7. Any unstable oncologic emergency syndromes: superior vena cava syndrome, rising&#xD;
             bilirubin needing stent placement, spinal cord compression, active bleeding, etc.&#xD;
&#xD;
          8. History of CNS metastasis, or other brain tumor, or history of stroke.&#xD;
&#xD;
          9. Radiation therapy within 6 weeks of Cycle 1 Week 1, or any radiation therapy which&#xD;
             encompasses target lesions selected for this study unless those lesions have&#xD;
             documented progression of disease.&#xD;
&#xD;
         10. Major surgery, open biopsy, or significant traumatic injury within 4 weeks of Cycle 1&#xD;
             Week 1, or anticipated need for major surgical procedure during the course of the&#xD;
             study.&#xD;
&#xD;
         11. Fine needle aspiration or placement of a central line catheter within 7 days of Cycle&#xD;
             1 Week 1.&#xD;
&#xD;
         12. Inadequate bone marrow, liver or kidney function defined as:&#xD;
&#xD;
               -  Serum creatinine more than 1.5 times the upper limit of normal,&#xD;
&#xD;
               -  Urine protein to creatinine ratio &gt;1,&#xD;
&#xD;
               -  Serum bilirubin &gt; 2 times the upper limit of normal,&#xD;
&#xD;
               -  ANC &lt; 1.5 x 109/L,&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 g / dL&#xD;
&#xD;
               -  Platelet count &lt; 90 x 109/L,&#xD;
&#xD;
               -  SGOT (AST) and SGPT (ALT) more than 3 times the upper limit of normal, or more&#xD;
                  than 5 times the upper limit of normal for subjects with documented liver&#xD;
                  metastases.&#xD;
&#xD;
         13. Myocardial infarction, transient ischemic attack, cerebral bleeding, translumenal&#xD;
             cardiac angiography or cardiac stent placement or other arterial thrombotic event&#xD;
             within 12 months prior to Cycle 1 Week 1.&#xD;
&#xD;
         14. Active, clinically significant cardiovascular or symptomatic arterial peripheral&#xD;
             vascular disease [e.g., uncontrolled hypertension, congestive heart failure,&#xD;
             claudication, unstable angina, symptomatic cardiac arrhythmia, or New York Heart&#xD;
             Association (NYHA) Class 2 or greater].&#xD;
&#xD;
         15. Presence of serious non-healing wounds, gastro-duodenal ulcers active by endoscopy,&#xD;
             gastro-intestinal perforation or intra-abdominal abscess, skin ulcers, or bone&#xD;
             fractures.&#xD;
&#xD;
         16. INR &gt;1.5 unless on therapeutic doses of oral anticoagulants (e.g. warfarin). If so,&#xD;
             must have an in-range INR (usually between 2-3) on a stable dose of drug.&#xD;
&#xD;
         17. Participation in another experimental drug study within 4 weeks prior to Cycle 1 Week&#xD;
             1.&#xD;
&#xD;
         18. Known or suspected anaphylaxis reaction to leucovorin or any allergic reaction to a&#xD;
             drug which, in the opinion of the Investigator, suggests an increased potential for a&#xD;
             hypersensitivity to CoFactor or other study drug including excipients.&#xD;
&#xD;
         19. Presence of organ allograft requiring immunosuppressive therapy.&#xD;
&#xD;
         20. Unwilling or unable to comply with the study protocol or history of psychiatric&#xD;
             disability judged by the investigator to preclude granting of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Wasif Saif, MD, MBBS</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Apple Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site In</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Port St. Lucie</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Tarpon Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Freesoil</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Lacey</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center In</name>
      <address>
        <city>Zrenjanin</city>
        <country>Former Serbia and Montenegro</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Former Serbia and Montenegro</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>June 14, 2006</study_first_submitted>
  <study_first_submitted_qc>June 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2006</study_first_posted>
  <last_update_submitted>November 15, 2007</last_update_submitted>
  <last_update_submitted_qc>November 15, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2007</last_update_posted>
  <keyword>Metastatic</keyword>
  <keyword>Colorectal</keyword>
  <keyword>Cancer</keyword>
  <keyword>CoFactor</keyword>
  <keyword>Stage IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

